Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a strong sell rating to a hold rating in a report released on Monday morning,Zacks.com reports.

Other research analysts have also recently issued research reports about the company. Sidoti upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price on the stock in a report on Wednesday, September 24th. Oppenheimer cut their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a report on Tuesday, October 21st. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Jefferies Financial Group reduced their target price on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research report on Monday, October 27th. Finally, Wall Street Zen lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $85.33.

Prestige Consumer Healthcare Stock Up 0.8%

Shares of PBH traded up $0.48 during mid-day trading on Monday, reaching $61.06. The company’s stock had a trading volume of 85,511 shares, compared to its average volume of 416,569. The company’s 50 day moving average is $62.71 and its 200 day moving average is $72.86. The stock has a market cap of $2.94 billion, a PE ratio of 14.32, a price-to-earnings-growth ratio of 1.93 and a beta of 0.41. Prestige Consumer Healthcare has a 12-month low of $59.18 and a 12-month high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.10. The business had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business’s quarterly revenue was down 3.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Equities analysts anticipate that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Large investors have recently made changes to their positions in the company. Cerity Partners LLC raised its stake in Prestige Consumer Healthcare by 3.7% during the 1st quarter. Cerity Partners LLC now owns 3,666 shares of the company’s stock valued at $315,000 after acquiring an additional 132 shares in the last quarter. UMB Bank n.a. raised its position in shares of Prestige Consumer Healthcare by 81.8% during the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after buying an additional 144 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of Prestige Consumer Healthcare by 2.0% in the second quarter. Bank of Montreal Can now owns 9,351 shares of the company’s stock valued at $747,000 after acquiring an additional 182 shares in the last quarter. Xponance Inc. increased its stake in shares of Prestige Consumer Healthcare by 5.5% during the first quarter. Xponance Inc. now owns 3,766 shares of the company’s stock valued at $324,000 after acquiring an additional 196 shares during the period. Finally, Resona Asset Management Co. Ltd. lifted its position in Prestige Consumer Healthcare by 2.3% in the first quarter. Resona Asset Management Co. Ltd. now owns 9,105 shares of the company’s stock worth $783,000 after purchasing an additional 203 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.